Azenta Inc Stock Price, News & Analysis

Azenta, Inc. (Nasdaq: AZTA) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, in San Francisco, CA. The management presentation is scheduled for 3:45 pm PST, and a live webcast will be accessible via the Azenta investor relations website. A replay will be available after the event. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services to support drug development and clinical research globally.

Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 25th Annual Needham Growth Conference on January 11, 2023, in New York, NY. The presentation will begin at 11:00 am ET and can be accessed via a live webcast on Azenta's investor relations website. Following the event, a replay will be available. Azenta is known for providing life sciences solutions, including cold-chain sample management and genomic services, aimed at accelerating breakthroughs in drug development and advanced therapies.

Cabot Corporation (NYSE: CBT) announced the promotion of three senior leaders to Executive Vice President: Hobart C. Kalkstein, Erica McLaughlin, and Jeff Zhu. Kalkstein oversees the Reinforcement Materials Segment, McLaughlin serves as CFO and Head of Corporate Strategy, and Zhu directs the Performance Chemicals Segment. CEO Sean Keohane praised their significant contributions and expressed excitement about their expanded roles in driving the company's growth strategy. This leadership enhancement is seen as a strategic move to bolster Cabot's performance and sustainability initiatives.

Azenta, Inc. (Nasdaq: AZTA) announced a $500 million accelerated share repurchase (ASR) agreement with JP Morgan Chase Bank to enhance shareholder value. This ASR is part of a larger $1.5 billion share repurchase authorization, with an additional $500 million planned for repurchases over the next year. The initial delivery will be approximately 6.1 million shares on November 28, 2022, and the final settlement is expected by June 30, 2023. The ASR aims to optimize capital allocation and boost earnings per share (EPS).

Azenta, Inc. (Nasdaq: AZTA) reported expected Q4'22 revenue of $138 million, marking no change year-over-year, with a 30% growth forecast for fiscal 2023. Excluding COVID impacts, organic growth reached 12% in Q4 and 17% for the year. The Board of Directors authorized a $1.5 billion share repurchase program, intending to buy back at least $1 billion of common stock. Despite a diluted EPS of ($0.07), management noted strong performance in life sciences services and a focus on growth alongside an acquisition of B Medical Systems.

Azenta, Inc. (Nasdaq: AZTA) has nominated Tina S. Nova, Ph.D., and Dorothy E. Puhy for election to its Board of Directors during the 2023 Annual General Meeting. Both nominees will join the Board as non-voting observers immediately. Nova brings over 25 years of experience in life sciences, previously leading companies that engaged in significant acquisitions, including Decipher Biosciences. Puhy, with extensive expertise from her tenure at Dana-Farber Cancer Institute, has held key leadership roles. This Board refreshment aims to enhance Azenta's strategic direction and support its transformation efforts.

Azenta, Inc. (Nasdaq: AZTA) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee on November 16, 2022. The presentation will start at 12:00 pm CT and can be accessed via a live webcast on Azenta's investor relations website. A replay will also be available post-event. Azenta provides comprehensive life sciences solutions, including cold-chain sample management and genomic services, supporting pharmaceutical and biotech sectors globally. For more details, visit Azenta's website.

Azenta, Inc. (Nasdaq: AZTA) and the Government of Luxembourg signed a Memorandum of Understanding (MoU) to enhance healthcare technology development in Luxembourg. This agreement, signed by Minister of Economy Franz Fayot and Azenta CEO Steve Schwartz, supports continued operations of B Medical Systems—recently acquired by Azenta. The MoU aims to foster collaboration on future research and innovation initiatives. Minister Fayot emphasized the importance of this partnership in showcasing Luxembourg's health technology sector. Azenta plans to leverage its global network to expand B Medical Systems' market reach.

Azenta, Inc. (Nasdaq: AZTA) will release its fiscal Q4 and full year 2022 earnings on November 14, 2022, after market close. A conference call will follow at 4:30 p.m. ET for analysts and investors, with access via phone and a live webcast on Azenta's website. The firm specializes in life sciences solutions and has recently rebranded from Brooks Automation. Azenta is focused on cold-chain sample management, drug development, and advanced cell therapies, operating globally across North America, Europe, and Asia.